hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06261905, orgStudyIdInfo id: 2000036908, secondaryIdInfos id: 000, type: OTHER, domain: CTGTY, briefTitle: Vitamin D in OUD: Exploration of Alterations on the Dopamine D2/D3 Receptor System, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-13, primaryCompletionDateStruct date: 2024-06, completionDateStruct date: 2024-06, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Yale University, class: OTHER, collaborators name: University of Pennsylvania, descriptionModule briefSummary: The research team is investigating Opioid Use Disorder (OUD), a disorder characterized by dysregulated dopaminergic tone, to evaluate the mechanisms of adjunctive treatment with calcitriol. The investigators will recruit 12 subjects with OUD and 12 healthy subjects to participate in a double-blind, randomized study design where subjects will complete up to 2 Positron Emission Tomography (PET) scans using \[11C\]-PHNO. The investigators will compare subjects in differences between their own study days and in differences between healthy control subjects and subjects with OUD., conditionsModule conditions: Opioid Use Disorder, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: This is primarily a within-subject, two scan, randomized, double-blind, placebo-controlled study design. Healthy control subjects will only complete one scan to serve as a baseline comparison for subjects with OUD., primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: [11C]-PHNO, interventions name: Calcitriol, interventions name: Placebo Control, interventions name: PET Scan, outcomesModule primaryOutcomes measure: Non-displaceable Tracer Binding Potentials (BPND), primaryOutcomes measure: Non-displaceable Tracer Binding Potentials (BPND), secondaryOutcomes measure: Spontaneous Blink Rate (SBR), secondaryOutcomes measure: Continuous Performance Task - Identical Pairs (CPT-IP), secondaryOutcomes measure: Probabilistic Reversal Learning Task (PRLT), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Yale School of Medicine, status: RECRUITING, city: New Haven, state: Connecticut, zip: 06510, country: United States, contacts name: Marcella Mignosa, role: CONTACT, phone: 203-903-7795, email: marcella.mignosa@yale.edu, contacts name: Adam Stryjewski, role: CONTACT, phone: 203-535-4424, email: adam.stryjewski@yale.edu, contacts name: Marc Potenza, MD, PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Gustavo Angarita, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 41.30815, lon: -72.92816, hasResults: False
protocolSection identificationModule nctId: NCT06261892, orgStudyIdInfo id: 2023-002, briefTitle: Non-invasive Biomarker Discovery for Pre-cervical or/and Cervical Cancer-HPV DNA and Other Biomarkers in Urine, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-07-20, primaryCompletionDateStruct date: 2025-06, completionDateStruct date: 2025-06, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: WomenX Biotech Limited, class: INDUSTRY, collaborators name: Hong Kong Science and Technology Parks Corporation, descriptionModule briefSummary: The goal of this clinical trial is1. To test the sensitivity and specificity of using HPV DNA from urine for the detection of pre-cervical or/and cervical cancer.2. If HPV DNA is not a promising biomarker, other biomarkers will be explored.3. To develop an effective and non-invasive detection method of the pre-cervical or/and cervical cancer. in Women with menstruation.The main question it aims to answer is:To validate whether HPV DNA from urine could be used as a non-invasive means for the detection of pre-cervical or cervical cancerParticipants will1. Join the briefing session of the study2. Sign the consent form and health questionnaire3. Submit the cervical medical report(s) within 3 months or perform sponsored pap smear test4. Collect the urine sampleIf there is a comparison group: Researchers will compare The diseased group and the healthy group according to the medical reports they provided to see if HPV DNA from urine is a promising biomarker for the detection of pre-cervical or cervical cancer, conditionsModule conditions: Cervical Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SCREENING, maskingInfo masking: NONE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: Collect HPV DNA from urine, outcomesModule primaryOutcomes measure: HPV DNA from urine is a promising biomarkers for the detection of pre-cervical/ cervical cancer, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: WomenX Biotech Limited, status: RECRUITING, city: Hong Kong, country: Hong Kong, contacts name: Alan LIU, Master, role: CONTACT, phone: +852 64786939, email: alanliu@womenx.net, geoPoint lat: 22.27832, lon: 114.17469, hasResults: False
protocolSection identificationModule nctId: NCT06261879, orgStudyIdInfo id: 2023-001, briefTitle: Non-invasive Biomarker Discovery for Pre-cervical or/and Cervical Cancer--ACTN4 and Other Biomarkers in Menstrual Blood, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-07-20, primaryCompletionDateStruct date: 2025-06, completionDateStruct date: 2025-06, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: WomenX Biotech Limited, class: INDUSTRY, descriptionModule briefSummary: The goal of this clinical trial is1. To test the sensitivity and specificity of using ACTN4 from menstrual blood for the detection of pre-cervical or/and cervical cancer.2. If ACTN4 is not a promising biomarker, other biomarkers will be explored.3. To develop an effective and non-invasive detection method for pre-cervical or/and cervical cancer.in Women with menstruation.The main question it aims to answer is:To validate whether menstrual blood could be used as a non-invasive means for the detection of pre-cervical or cervical cancerParticipants will1. Join the briefing session of the study2. Sign the consent form and health questionnaire3. Submit the cervical medical report(s) within 3 months or perform sponsored pap smear test4. Collect the menstrual blood sampleIf there is a comparison group: Researchers will compare The diseased group and the healthy group according to the medical reports they provided to see if ACTN4 from menstrual blood is a promising biomarker for the detection of pre-cervical or cervical cancer, conditionsModule conditions: Cervical Cancer, conditions: CIN, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SCREENING, maskingInfo masking: NONE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: Special sanitary pad, outcomesModule primaryOutcomes measure: ACTN4 is a promising biomarkers for the detection of pre-cervical/ cervical cancer, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: WomenX Biotech Limited, status: RECRUITING, city: Hong Kong, country: Hong Kong, contacts name: Alan LIU, Master, role: CONTACT, phone: +852 64786939, email: alanliu@womenx.net, geoPoint lat: 22.27832, lon: 114.17469, hasResults: False
protocolSection identificationModule nctId: NCT06261866, orgStudyIdInfo id: MultiInter-CCS, briefTitle: Multimodality Imaging and Functional Lesion Assessment in Intermediate Coronary Stenosis in Chronic Coronary Syndrome, acronym: MultiInter-CCS, statusModule overallStatus: RECRUITING, startDateStruct date: 2011-04-07, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2028-12-31, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: Medical University of Warsaw, class: OTHER, descriptionModule briefSummary: The aim of this prospective, investigator-initiated study is to evaluate the diagnostic accuracy and correlations between functional indices (fractional flow reserve, FFR) and morphometric indices: luminal and qualitative parameters assessed by optical coherence tomography (OCT) including minimal lumen area, plaque type, presence of thin cap fibroatheroma among patients with chronic coronary syndrome identified with intermediate grade coronary stenosis., conditionsModule conditions: Chronic Coronary Syndrome, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Correlation between fractional flow reserve (FFR) and minimal lumen area within the coronary stenosis, primaryOutcomes measure: Correlation between fractional flow reserve (FFR) and mean lumen area within the coronary stenosis, secondaryOutcomes measure: Major adverse cardiovascular events, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Medical University of Warsaw, status: RECRUITING, city: Warsaw, country: Poland, contacts name: Mariusz Tomaniak, MD, PhD, Assoc. Prof., role: CONTACT, email: mariusz.tomaniak@wum.edu.pl, contacts name: Piotr Baruś, MD, role: CONTACT, email: piotr.barus@wum.edu.pl, geoPoint lat: 52.22977, lon: 21.01178, hasResults: False
protocolSection identificationModule nctId: NCT06261840, orgStudyIdInfo id: 2024-101, briefTitle: Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-01, primaryCompletionDateStruct date: 2029-05-01, completionDateStruct date: 2029-07-31, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: Tulane University, class: OTHER, collaborators name: University of Alabama at Birmingham, collaborators name: Louisiana State University Health Sciences Center in New Orleans, descriptionModule briefSummary: This is a multi-centered, randomized, open-label, parallel, phase IV clinical trial comparing the effectiveness and cost-effectiveness of oral multi-dose metronidazole (MTZ) and oral single-dose secnidazole (SEC) for the treatment of Trichomonas vaginalis in both women and men., conditionsModule conditions: Trichomonas Vaginitis, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 1200, type: ESTIMATED, armsInterventionsModule interventions name: Metronidazole 500 mg, interventions name: Secnidazole 2000 MG, outcomesModule primaryOutcomes measure: Treatment, as Measured by the Number of Participants that are Cured of Trichomonas Vaginalis, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06261814, orgStudyIdInfo id: iRISID-2023-2142, briefTitle: Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08-31, primaryCompletionDateStruct date: 2027-07-01, completionDateStruct date: 2028-01-01, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: john eisenbrey, class: OTHER, descriptionModule briefSummary: This phase II trial evaluates the diagnostic performance of contrast-enhanced ultrasound (CEUS) for assessing treatment response in patients undergoing transarterial chemoembolization (TACE) for liver tumors. TACE is a hepatic artery embolization technique involving the injection of a blocking agent and a chemotherapy agent to treat liver cancers. Currently, contrast enhanced magnetic resonance imaging or computed tomography are used to assess disease response 1-2 months after TACE treatment, but ultrasound may be a less expensive, earlier alternative. CEUS is an imaging procedure that uses high-frequency sound waves to generate images of the body after administering lumason, an imaging agent used to enhance visualization of blood flow on ultrasounds. CEUS is able to be performed during the TACE procedure, making it possible to evaluate treatment response earlier than standard techniques. CEUS may be an effective method to evaluate treatment response more accurately and much earlier than current standard evaluation methods., conditionsModule conditions: Liver Neoplasms, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: No Data Available, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 266, type: ESTIMATED, armsInterventionsModule interventions name: Sulfur Hexafluoride Lipid Microspheres, interventions name: Contrast-Enhanced Ultrasound, interventions name: Transarterial Chemoembolization, interventions name: Medical Chart Review, outcomesModule primaryOutcomes measure: Recurrence, primaryOutcomes measure: Specificity, primaryOutcomes measure: Positive predictive value, primaryOutcomes measure: Negative predictive value, primaryOutcomes measure: False discovery rate, secondaryOutcomes measure: Residual tumor vacularity, secondaryOutcomes measure: Diagnostic performance for each imaging mode, secondaryOutcomes measure: Ability of the model to predict binary treatment response, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sidney Kimmel Cancer Center at Thomas Jefferson University, city: Philadelphia, state: Pennsylvania, zip: 19107, country: United States, geoPoint lat: 39.95233, lon: -75.16379, hasResults: False
protocolSection identificationModule nctId: NCT06261801, orgStudyIdInfo id: GZY-ZJ-KJ-23088, briefTitle: Efficacy of Electroacupuncture Combined With Pregabalin in the Treatment of Trigeminal Herpetic Neuralgia: a Multicenter Randomized Controlled Trial Study Protocol, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-07, primaryCompletionDateStruct date: 2025-07-20, completionDateStruct date: 2025-12-20, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: The Third People's Hospital of Hangzhou, class: OTHER, collaborators name: The Third Affiliated hospital of Zhejiang Chinese Medical University, descriptionModule briefSummary: Trigeminal herpetic neuralgia is a common type of Zoster-associated Pain (ZAP), which troubles individuals in all ages and burdens society all over the world. Eleactroaupuncture (EA) is increasingly used in the treatment of ZAP due to its advantages such as low price, high safety, no adverse reactions, and high patient acceptance. Therefore, it is necessary to conduct randomized controlled trials to evaluate the effectiveness and safety of EA on ZAP and whether EA can be used as a substitute for pregabalin., conditionsModule conditions: Trigeminal Herpetic Neuralgia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 102, type: ESTIMATED, armsInterventionsModule interventions name: Medication Group, interventions name: EA Group, interventions name: EA+Medication Group, outcomesModule primaryOutcomes measure: Visual Analog Score change, secondaryOutcomes measure: McGill Pain Questionnaire Short Form (SF-MPQ), secondaryOutcomes measure: Brief Pain Inventory Scale (BPI-SF), secondaryOutcomes measure: Medical Outcomes Study Sleep Scale (MOS-SS), secondaryOutcomes measure: Hamilton Depression Rating Scale (HAMD)Hamilton Anxiety Rating Scale (HAMA), secondaryOutcomes measure: Hamilton Depression Rating Scale (HAMD), secondaryOutcomes measure: Short Form 36 Health Survey (SF-36), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The Hangzhou Third People's Hospital, status: RECRUITING, city: Hangzhou, state: Zhejiang, zip: 310009, country: China, contacts name: Pin Lin, role: CONTACT, phone: 1358876268686, email: yjlp1@163.com, contacts name: Chengcheng Kong, role: CONTACT, phone: 8613868078286, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06261788, orgStudyIdInfo id: EASY II Trial, briefTitle: Efficacy and Safety of the Sync-AV II Temporary Cardiac Pacing Catheter, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-06-01, primaryCompletionDateStruct date: 2023-09-13, completionDateStruct date: 2023-09-26, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: Swift Sync, Inc., class: INDUSTRY, collaborators name: Regulatory and Quality Solutions, descriptionModule briefSummary: This is a prospective, single-center, non-randomized open label study. The objective of this study is to evaluate the efficacy and safety of the Sync-AV II Temporary Cardiac Pacing Catheter in subjects whose elective surgical or interventional procedure require temporary pacing support., conditionsModule conditions: Heart Block, conditions: Valve Heart Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ACTUAL, armsInterventionsModule interventions name: Temporary pacing, outcomesModule primaryOutcomes measure: With a commercially available pacing box and/or analyzer, measure the ventricular pacing threshold at 24 hours post implant of the investigational device (index procedure), primaryOutcomes measure: Procedure related complications, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Centro de Intervenciones Endovasculares y Cirugia Cardiovascular, city: Asunción, country: Paraguay, geoPoint lat: -25.30066, lon: -57.63591, hasResults: False
protocolSection identificationModule nctId: NCT06261775, orgStudyIdInfo id: IRB-2401011-EXM, briefTitle: Effect of Minimally Processed Animal Protein on Biomarkers for Cognitive Decline, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-01-30, primaryCompletionDateStruct date: 2024-02-07, completionDateStruct date: 2026-01-02, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: South Dakota State University, class: OTHER, descriptionModule briefSummary: Minimally processed animal protein is a premier source of essential macro and micronutrients in the diet and is important, especially to older adults who are at increased risk of nutritional deficiency and age-related physiological changes. Our central hypothesis is that adding lean animal protein within a dietary guideline-based diet will enhance nutrient adequacy and attenuate markers of cognitive decline. This is a retrospective study leveraging samples collected from the feeding trial NCT05581953. PI for both studies are the same., conditionsModule conditions: Healthy Lifestyle, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 36, type: ACTUAL, armsInterventionsModule interventions name: Red meat-based meal, interventions name: Lacto-ovo-vegetarian meal, outcomesModule primaryOutcomes measure: Concentration of phosphatidylcholine in blood, eligibilityModule sex: ALL, minimumAge: 65 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: South Dakota State University, Wagner Hall 416, city: Brookings, state: South Dakota, zip: 57007, country: United States, geoPoint lat: 44.31136, lon: -96.79839, hasResults: False
protocolSection identificationModule nctId: NCT06261762, orgStudyIdInfo id: SDC-24-1, briefTitle: Hard and Soft Tissue Dimensional Change After Consecutive Extractions and Unassisted Socket Healing in the Esthetic Zone, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-29, primaryCompletionDateStruct date: 2026-06-30, completionDateStruct date: 2026-06-30, studyFirstPostDateStruct date: 2024-02-15, lastUpdatePostDateStruct date: 2024-02-15, sponsorCollaboratorsModule leadSponsor name: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to evaluate the post-extraction hard and soft tissue dimension changes in patients requiring consecutive extractions and unassisted socket healing in the anterior maxilla. The main questions it aims to answer are:* Is significant alveolar ridge resorption observed at center sites after consecutive extractions* Is significant alveolar ridge resorption observed at the interalveolar septum after consecutive extractions, are different extraction sites associated with significantly different bone resorption* Is a thick or thin wall phenotype associated with the amount of bone resorption* Is soft tissue thickness change associated with the corresponding location (extraction site or interalveolar septum) and post-extraction thickness of the bone* Is the interdental papilla height significantly affected after extractions.Participants will undergo consecutive (two) extractions and will be evaluated after subsequent unassisted socket healing for 8 weeks., conditionsModule conditions: Wound Heal, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 20, type: ESTIMATED, outcomesModule primaryOutcomes measure: Bone level change from baseline, primaryOutcomes measure: Soft tissue change from baseline, secondaryOutcomes measure: Correlation between baseline facial bone thickness and dimensional soft tissue alterations during healing at the interalveolar septum., eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False